Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
Matthias PreusserAntonio SilvaniEmilie Le RhunRiccardo SoffiettiGiuseppe LombardiJuan Manuel SepulvedaPetter BrandalLucy BrazilAlice Bonneville-LevardVeronique LorgisElodie VauleonJacoline BrombergSara ErridgeAlison CameronFlorence LefrancPaul M ClementSarah DumontMarc SansonCharlotte BronnimannCarmen BalanáNiklas ThonJoanne LewisMaximilian J MairPhilipp SieversJulia FurtnerJosef PichlerJordi BrunaFrancois DucrayJaap C ReijneveldChristian MawrinMartin BendszusChristine MarosiVassilis GolfinopoulosCorneel CoensThierry GorliaMichael WellerFelix SahmWolfgang WickPublished in: Neuro-oncology (2021)
Trabectedin did not improve PFS and OS and was associated with higher toxicity than LOC treatment in patients with non-benign meningioma. Tumour DNA methylation class is an independent prognostic factor for OS.